CureVac (NASDAQ:CVAC) Shares Gap Down to $2.94

CureVac (NASDAQ:CVAC)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $2.94, but opened at $2.81. CureVac shares last traded at $2.92, with a volume of 282,063 shares changing hands.

CureVac Stock Performance

The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average price is $3.48 and its 200-day moving average price is $5.01.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. boosted its stake in shares of CureVac by 95.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company’s stock worth $39,000 after acquiring an additional 2,804 shares in the last quarter. Vontobel Holding Ltd. acquired a new position in shares of CureVac in the 4th quarter valued at $45,000. Optiver Holding B.V. increased its stake in CureVac by 2,407.0% in the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock worth $47,000 after purchasing an additional 6,571 shares in the last quarter. Pathstone Holdings LLC acquired a new stake in CureVac during the 4th quarter worth about $55,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in CureVac during the first quarter valued at about $59,000. Institutional investors and hedge funds own 15.76% of the company’s stock.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.